(HealthDay News) — Androgen-deprivation therapy with radiotherapy (ADT plus RT) is associated with a survival advantage over ADT alone for older men with locally advanced or screen-detected high-risk prostate cancer, according to a study published online January 5 in the Journal of Clinical Oncology.
Justin E. Bekelman, MD, from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted nonrandomized effectiveness studies of ADT plus RT vs. ADT in three cohorts of patients diagnosed between 1995–2007. The randomized clinical trial (RCT) cohort included men aged 65–75 years; the elderly cohort included men aged >75 years with locally advanced disease; and the screen-detected cohort included men aged ≥65 years with screen-detected high-risk prostate cancer.
The researchers found that ADT plus RT correlated with reduced cause-specific and all-cause mortality compared with ADT alone in the RCT cohort (propensity score-adjusted hazard ratios, 0.43 and 0.63, respectively). There was no significant difference in effectiveness estimates for the RCT cohort vs. those from randomized trials (P>0.1). ADT plus RT correlated with reduced cause-specific and all-cause mortality in the elderly and screen-detected cohorts. Similar estimates were produced in instrumental variable analyses.
“Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival,” the authors write.